🔔 What This Document Is

This is a Form 8-K filing, specifically Exhibit 99.1. Think of an 8-K as a company's "urgent bulletin board" for major events that shareholders should know about. This particular bulletin is an official announcement that Supernus will release its Q1 2026 financial results on May 5, 2026, and host a conference call for investors afterward.

👉 Why it matters: It formally puts the market on notice about when to expect the company's next financial update, helping prevent surprises and ensuring everyone has the same information.

🧠 What The Company Does

In simple terms, Supernus Pharmaceuticals is a brain-focused drug company. They specialize in developing and selling medications for diseases of the central nervous system (CNS). Their current portfolio already treats conditions like ADHD, Parkinson's disease symptoms, epilepsy, and postpartum depression. They are also working on developing new drugs for other brain-related disorders.

📅 Key Dates & Logistics

The critical information here is when everything is happening:

• Financial Results Release: After the stock market closes on Tuesday, May 5, 2026.
• Live Conference Call: Tuesday, May 5, 2026, at 4:30 p.m. ET.
• Replay Available: The webcast will be archived on their investor relations site for 60 days after the live call.

👉 Key takeaway: Mark your calendar for May 5th. The results come out after the close of trading, so the first chance the public has to react is the next trading day.

👥 Who Will Be Talking

Two key executives will lead the call:

1. Jack Khattar, President and CEO (the company's leader).
2. Tim Dec, Senior Vice President and CFO (the head of finance). They will present the results and then answer questions from analysts and investors.

📞 How to Access the Call

The filing gives clear instructions for anyone wanting to listen in:

• Webcast: The best way is through the "Events & Presentations" section of their Investor Relations website: www.supernus.com/investors
• Phone Access: You can pre-register online anytime before the call to get a unique dial-in number and conference code.
• Tip: If dialing in, do so 15 minutes early to get connected smoothly.

👉 For investors: This is your direct channel to hear management's perspective on the quarter's performance and their strategic plans.

💼 Why This Announcement Matters

Even though this isn't the earnings report itself, this filing is important for a few reasons:

1. Transparency: It shows the company is following SEC rules to communicate openly with investors.
2. Preparation: It gives analysts, investors, and the media time to clear their schedules and prepare questions.
3. Signals Timing: The timing of the release (after market close) is standard practice to allow time for the market to digest the news before trading opens the next day.

🔗 The Contacts

For media or investor inquiries, two key points of contact are provided:

• Company Executives: Jack A. Khattar (CEO) and Timothy C. Dec (CFO) can be reached at (301) 838-2591.
• Investor Relations Firm: Peter Vozzo at ICR Healthcare handles investor questions. His direct line is (443) 213-0505, and his email is [email protected].

🧠 The Analogy

Think of this filing as a company sending out a "Save the Date" invitation for a big reveal party. The party is the earnings release on May 5th, where they'll unveil how they performed. This document is the formal invitation that tells everyone when and where to show up to hear the news firsthand.

🧩 Final Takeaway

Supernus Pharmaceuticals is formally inviting the market to hear its first-quarter 2026 financial results after the market closes on May 5, 2026. This is a routine but important administrative step that ensures all investors have equal access to upcoming information. The real story will come on the conference call that same afternoon.